We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Baclofen for Treatment of Muscle Spasms in Patients With Cirrhosis: A Pilot Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02298868
Recruitment Status : Completed
First Posted : November 24, 2014
Results First Posted : February 5, 2015
Last Update Posted : February 5, 2015
Sponsor:
Information provided by (Responsible Party):
Zachary Henry, MD, University of Virginia

Brief Summary:
The purpose of this study is to determine the safety and efficacy of the medication Baclofen for treatment of muscle cramps in patients with cirrhosis.

Condition or disease Intervention/treatment Phase
Muscle Cramps Cirrhosis Drug: Baclofen Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Baclofen for Treatment of Muscle Spasms in Patients With Cirrhosis: A Pilot Study
Study Start Date : October 2012
Actual Primary Completion Date : November 2013
Actual Study Completion Date : November 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Muscle Cramps
Drug Information available for: Baclofen

Arm Intervention/treatment
Experimental: Treatment
All patients will be administered a standing dose of Baclofen initially at 5 mg three times a day for the first week and then increased to 10 mg three times a day for the next 3 weeks with a tapering dose the final week, a total of 5 weeks of therapy.
Drug: Baclofen



Primary Outcome Measures :
  1. Number of Participants With Adverse Events as a Measure of Safety and Tolerability (Headache) [ Time Frame: 4 weeks of active therapy ]
    Proportion of patients with headache at any time during the 4 weeks of therapy

  2. Number of Participants With Adverse Events as a Measure of Safety and Tolerability (Nausea) [ Time Frame: 4 weeks of active therapy ]
    Proportion of patients with nausea at any time during the 4 weeks of therapy

  3. Number of Participants With Adverse Events as a Measure of Safety and Tolerability (Dizziness) [ Time Frame: 4 weeks of active therapy ]
    Proportion of patients with dizziness at any time during the 4 weeks of therapy

  4. Number of Participants With Adverse Events as a Measure of Safety and Tolerability (Encephalopathy) [ Time Frame: 4 weeks of active therapy ]
    Proportion of patients with endephalopathy at any time during the 4 weeks of therapy

  5. Number of Participants With Adverse Events as a Measure of Safety and Tolerability (Somnolence) [ Time Frame: 4 weeks of active therapy ]
    Proportion of patients with somnolence at any time during the 4 weeks of therapy


Secondary Outcome Measures :
  1. Efficacy of Baclofen to Change Frequency of Muscle Cramps in Patients With Cirrhosis at the End of 4 Weeks of Therapy [ Time Frame: Baseline to 4 weeks of therapy ]
    Patients undertook a muscle cramp questionnaire prior to treatment that measured frequency in the number of days in a week that a subject experienced muscle cramps. This measures was repeated after 4 weeks of therapy and reported as the mean decrease in frequency of muscle cramps (4 weeks of therapy-Baseline).

  2. Efficacy of Baclofen to Change Severity of Muscle Cramps in Patients With Cirrhosis After 4 Weeks of Therapy [ Time Frame: Baseline to end of 4 weeks of therapy ]
    Patients undertook a muscle cramp questionnaire prior to treatment that measured severity in a 0-10 analog scale (0 is no pain and 10 is most severe pain). These measures were repeated after 4 weeks of therapy and the difference was assessed (4 weeks of therapy-Baseline).

  3. Change in Frequency of Muscle Cramps After Washout Period [ Time Frame: End of treatment (week 4) to end of washout (week 7) ]
    Subjects undertook a muscle cramp questionnaire prior to treatment that measured frequency in the number of days in a week that a subject experienced muscle cramps and repeated this measure at the end of baclofen therapy (end of week 4). Subjects then underwent a 1 week taper of baclofen and a subsequent two week washout period. At the end of the washout period (end of week 7) the subjects underwent a final muscle cramp questionnaire to reassess frequency of muscle cramps. This was then compared to the end of therapy frequency to document the increase in muscle cramps after stopping baclofen. (week 7 result - week 4 result)

  4. Change in Severity of Muscle Cramps After Washout Period [ Time Frame: End of treatment (week 4) to end of washout (week 7) ]
    Subjects undertook a muscle cramp questionnaire prior to treatment that measured severity on a 0-10 analog scale (0 is no pain, 10 is most severe pain) and repeated this measure at the end of baclofen therapy (end of week 4). Subjects then underwent a 1 week taper of baclofen and a subsequent two week washout period. At the end of the washout period (end of week 7) the subjects underwent a final muscle cramp questionnaire to reassess severity of muscle cramps. This was then compared to the end of therapy severity to document the increase in muscle cramps after stopping baclofen. (week 7 result - week 4 result)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Cirrhosis
  • Presence of muscle cramps on a regular basis

Exclusion Criteria:

  • Allergy or hypersensitivity to Baclofen
  • Active or untreated Portosystemic encephalopathy
  • Active alcohol or substance abuse
  • Age less than 18
  • Pregnancy
  • Concomitant use of narcotic pain medication, other muscle relaxer, or other anti-spastic agent
  • Concomitant use of Tricyclic Antidepressant due to drug interaction
  • History of chronic kidney disease defined by GFR < 30 (using MDRD equation)
  • Subject is institutionalized or a prisoner
  • Inability or unwillingness to give informed consent
  • Expected lifespan less than 3 months
  • Severe or poorly controlled coexisting medical conditions or other significant issues as determined by the principal investigator to hinder the ability to adhere to study protocols

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02298868


Sponsors and Collaborators
University of Virginia
Investigators
Layout table for investigator information
Principal Investigator: Zachary Henry, M.D. University of Virginia
Layout table for additonal information
Responsible Party: Zachary Henry, MD, Fellow Physician, University of Virginia
ClinicalTrials.gov Identifier: NCT02298868    
Other Study ID Numbers: 16306
First Posted: November 24, 2014    Key Record Dates
Results First Posted: February 5, 2015
Last Update Posted: February 5, 2015
Last Verified: February 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscle Cramp
Liver Cirrhosis
Spasm
Fibrosis
Pathologic Processes
Liver Diseases
Digestive System Diseases
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Baclofen
Muscle Relaxants, Central
Physiological Effects of Drugs
Neuromuscular Agents
Peripheral Nervous System Agents
GABA-B Receptor Agonists
GABA Agonists
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action